4-乙基哌嗪-1-羧酸乙酯 | 98951-41-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-乙基哌嗪-1-羧酸乙酯
• 英文名称: 4-ethyl-piperazine-1-carboxylic acid ethyl ester
• 英文别名: 4-Aethyl-piperazin-1-carbonsaeure-aethylester；ethyl 4-ethyl-1-piperazine carboxylate；1-Piperazinecarboxylic acid, 4-ethyl-, ethyl ester；ethyl 4-ethylpiperazine-1-carboxylate
• CAS: 98951-41-8
• 化学式: C₉H₁₈N₂O₂
• mdl: MFCD03392097
• 分子量: 186.254
• InChiKey: DMHCQRMESDDXNG-UHFFFAOYSA-N

物化性质

• 沸点：
  132 °C(Press: 28 Torr)
• 密度：
  1.033±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-乙基哌嗪-1-羧酸乙酯 在 盐酸 作用下， 生成 N-乙基哌嗪
  参考文献：
  名称：

  Unsymmetrically N-Substituted Piperazines. VIII. Amide Derivatives¹

  摘要：

  DOI：

  10.1021/ja01616a072
• 作为产物：
  描述：

  N-乙基哌嗪 、 氯甲酸乙酯 在 吡啶 作用下， 生成 4-乙基哌嗪-1-羧酸乙酯
  参考文献：
  名称：

  Al-Otaibi, Faisal, Acta poloniae pharmaceutica, 2018, vol. 75, # 3, p. 649 - 658

  摘要：

  DOI：

文献信息

• Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
  申请人：NEUROSEARCH A/S

  公开号：US20040097570A1

  公开（公告）日：2004-05-20

  The present invention relates to novel benzimidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABA A receptor complex, and in particular for inducing and maintaining anesthesia, sedation and muscle relaxation, as well as for combating febrile convulsions in children. The compounds of the invention may also be used by veterinarians.

  本发明涉及新型苯并咪唑衍生物，包含这些化合物的制药组合物，以及使用它们的治疗方法。该发明的化合物在治疗对GABAA受体复合物调节有响应的中枢神经系统疾病和疾病方面具有用途，特别是用于诱导和维持麻醉、镇静和肌肉松弛，以及对儿童的热性惊厥进行抗击。该发明的化合物也可以被兽医使用。
• Methods and compositions of novel triazine compounds
  申请人：Timmer T. Richard

  公开号：US20070043051A1

  公开（公告）日：2007-02-22

  The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

  本发明涉及使用化合物治疗由炎症反应引起的病理生理状况的方法和组合物。具体而言，本发明涉及抑制或阻断糖基化蛋白诱导内皮细胞中与信号相关的炎症反应的化合物。本发明涉及抑制平滑肌增殖的化合物。具体而言，本发明涉及通过调节HSPGs（如Perlecan）来抑制平滑肌细胞增殖的化合物。本发明进一步涉及使用化合物治疗以平滑肌增殖为特征的血管闭塞性疾病，如再狭窄和动脉粥样硬化。
• DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS
  申请人：Adler Marc

  公开号：US20080176833A1

  公开（公告）日：2008-07-24

  This invention provides novel dihydropyridine derivatives of the formula I having protein tyrosine kinase inhibitory activity, to process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions.

  本发明提供了一种具有蛋白酪氨酸激酶抑制活性的新型二氢吡啶衍生物，以及其制造方法和用于治疗c-Met介导的疾病或c-Met介导的病状的用途。
• INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF
  申请人：Jagtap Prakash

  公开号：US20100121049A1

  公开（公告）日：2010-05-13

  The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog.

  本发明涉及吲哚异喹啉衍生物，包括含有效量的吲哚异喹啉衍生物的组合物及其用于治疗或预防炎症性疾病、再灌注损伤、糖尿病、糖尿病并发症、器官移植所致的再氧化损伤、缺血症、神经退行性疾病、肾衰竭、血管疾病、心血管疾病、癌症、早产并发症、心肌病、视网膜病、肾病、神经病变、勃起功能障碍或尿失禁的方法，包括向需要治疗的受体中投与有效量的吲哚异喹啉衍生物。
• EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS
  申请人：The Regents of the University of California

  公开号：US20160244435A1

  公开（公告）日：2016-08-25

  Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to imidazole, thiazole, and furan derivatives and their use as therapeutic agents.

  本文披露了抗微生物化合物组成物、制药组合物、其使用和制备方法。其中一些实施例涉及咪唑、噻唑和呋喃衍生物及其作为治疗剂的使用。